TEM - Tempus AI Inc
Executive Summary
Tempus AI Inc is a US-listed technology company that applies artificial intelligence to precision medicine, with operations spanning genomics testing and data services for healthcare providers, biopharma, and research institutions. It operates within the Software - Application industry and is positioned as a leading adopter of AI-driven clinical and molecular data workflows, though profitability has not yet been achieved.
The investment case hinges on continued acceleration of revenue growth, execution on recently disclosed contracts and acquisitions, and the ability to demonstrate a credible path to Adjusted EBITDA profitability. The key near-term catalyst is the next scheduled earnings release on 6 August 2026 (after the close), where management is expected to confirm progress against the raised full-year 2026 revenue guidance of USD1.59 to USD1.60 billion and the approximately USD65 million Adjusted EBITDA target set in Q1 2026 results. The primary risk is that GAAP net losses widen further as stock-based compensation and unrealised securities losses persist, weighing on cash earnings and investor sentiment.
Bottom line: OPPORTUNISTIC BUY. Conviction Score: 59/100. The view would upgrade on sustained margin expansion combined with a clear narrowing of GAAP losses, and would degrade sharply if quarterly revenue growth re-accelerates only on lower-quality, low-margin revenue or if insider selling intensifies.
Business Model
Tempus AI generates revenue from two principal segments: Genomics, which comprises molecular profiling and laboratory testing services sold primarily to oncologists, hospitals, and biopharma sponsors; and Data and Services, which monetises de-identified clinical and molecular datasets, AI-derived insights, and platform access for pharmaceutical research and development customers. Customers are largely institutional - hospital systems, academic medical centres, and biopharma companies - with revenue concentrated in the United States. Pricing is contract-based, with multi-year data licences supplementing fee-for-service testing volumes.
The reported Q1 2025 results illustrate the operating model: quarterly revenue reached USD255.7 million, up 75.4 per cent year-over-year, with quarterly gross profit of USD155.2 million, up 99.8 per cent year-over-year, reflecting gross margin expansion in both the Genomics and Data and services segments. The company is scaling rapidly from a low revenue base, which produces strong percentage growth but has not yet translated into profitability: Q1 2025 produced a reported net loss of USD68.0 million, including USD28.2 million of stock compensation expense and related employer payroll taxes. Full-year 2026 revenue guidance of USD1.59 to USD1.60 billion and an Adjusted EBITDA target of approximately USD65 million underscore management's intent to reach operating profitability on an adjusted basis while GAAP profitability remains constrained by non-cash items.
The competitive moat, where it exists, rests on the breadth of the proprietary multimodal clinical-genomic dataset and the recurring nature of biopharma data engagements. Switching costs are meaningful for customers that have embedded Tempus workflows into clinical decision-making, and accumulated molecular and clinical records grow more valuable as additional data is added. However, the moat is not absolute - competing offerings from other technology-enabled diagnostics and AI-healthcare platforms exist, and sustained differentiation depends on continued dataset expansion and productisation of AI models.
Financial Snapshot
Recent Catalysts
[5 May 2026] - Tempus reported first-quarter 2026 results, raising full-year 2026 revenue guidance to USD1.59 to USD1.60 billion and guiding to full-year Adjusted EBITDA of approximately USD65 million, citing strong financial momentum. Source: Tempus AI press release via BusinessWire.
[4 June 2026] - A reported FDA-related development fuelled a sharp intraday move higher in TEM shares, with coverage noting upward price action of approximately 9.81 per cent on the day and bullish momentum around an AI healthcare update. Source: StocksToTrade newswire.
[3 June 2026] - Tempus issued a corporate announcement dated 3 June 2026 from its Chicago headquarters, the substance of which is summarised on the company's official news page. Source: Tempus AI corporate news page (tempus.com/news/).
[1 June 2026] - Wolfe Research assumed coverage of TEM with a Peer Perform rating, while separate reporting flagged the upcoming clinical availability of an unspecified Tempus product. Source: CNN Markets, citing TipRanks-summarised analyst commentary.
[6 August 2026 (after the close)] - Tempus AI is scheduled to release its next quarterly results, with the date confirmed as 6 August 2026 after market close. Source: TipRanks earnings calendar.
Thesis Evaluation
Bull Case (25% weight)
Tempus sustains revenue growth above 60 per cent year-over-year through 2026, executes the raised USD1.59 to USD1.60 billion full-year guidance, and delivers the approximately USD65 million Adjusted EBITDA target while gross margins continue to expand. The company secures additional multi-year biopharma data contracts and converts the recently disclosed USC partnership into visible, contract-attributable revenue. Under these conditions a 12-month target of $78 is plausible, reflecting multiple expansion as Adjusted EBITDA inflection approaches.
Base Case (50% weight)
Revenue growth normalises into the 40 to 55 per cent range as the comparables toughen, with full-year 2026 revenue landing near the midpoint of guidance at roughly USD1.60 billion and Adjusted EBITDA tracking close to USD65 million, but GAAP losses persist on stock compensation. Insider sales continue at a measured pace and the share price re-rates modestly as adjusted profitability is confirmed. Under this base case a 12-month target of $58 is realistic.
Bear Case (25% weight)
Growth decelerates materially below 40 per cent, the USC partnership fails to translate into a material contract pipeline, and stock-based compensation or unrealised securities losses widen the GAAP net loss, eroding investor patience. Insider selling accelerates and the multiple compresses toward software-application peers without a profitability offset. Under these conditions a 12-month downside target of $32 is plausible.
Key Risks
- Persistent GAAP losses and stock-based compensation: Tempus has reported recurring net losses and disclosed material stock-based compensation expense, which could continue to suppress GAAP profitability and pressure the multiple. Estimated probability: 70%. Impact: severe.
- Insider share sales by CEO-linked entities: Filing-disclosed sales of approximately USD9.6 million in shares by entities linked to the chief executive have been noted and could weigh on sentiment if repeated. Estimated probability: 50%. Impact: moderate.
- Customer concentration in biopharma and US healthcare: Revenue depends on a relatively concentrated set of biopharma and US hospital customers, exposing the model to contract loss, procurement pressure, or US reimbursement shifts. Estimated probability: 35%. Impact: severe.
- AI-healthcare competitive intensity: Competing AI-driven diagnostics and data platforms could compress pricing or slow customer wins, eroding the differentiation from Tempus's proprietary dataset. Estimated probability: 45%. Impact: moderate.
- Regulatory and reimbursement risk: Changes to FDA clearance pathways, clinical laboratory regulation, or payer reimbursement for genomic testing could affect genomics volumes and gross margins. Estimated probability: 30%. Impact: severe.
Who Should Own It / Avoid It
Ideal for: growth-oriented investors with a high risk tolerance and a minimum 18 to 24 month holding horizon, who can absorb GAAP losses and meaningful share-price volatility in exchange for exposure to AI-enabled precision medicine and a company in the late stages of reaching adjusted profitability. The position size should reflect both the unprofitable profile and the elevated insider activity.
Avoid if: investors require current GAAP profitability, cannot tolerate double-digit drawdowns, rely on near-term income, or are constrained by mandates that exclude pre-profit software-application names. Conservative investors and those with mandates tied to near-term earnings should also look elsewhere.
Recommendation
OPPORTUNISTIC BUY - 59/100. The combination of raised full-year 2026 revenue guidance to USD1.59 to USD1.60 billion, an Adjusted EBITDA target of approximately USD65 million, and hard catalysts including the 6 August 2026 earnings release and the USC partnership support a constructive stance, but GAAP losses, stock-based compensation, and insider sales cap conviction. The call would upgrade on confirmation of adjusted profitability alongside narrowing GAAP losses and disciplined insider activity; it would degrade to HOLD or SELL on a meaningful revenue miss, a guidance cut, or a sharp acceleration in insider selling. At the current price of $43.87 the shares trade above our buy ceiling of $40.67: the thesis is credible but the price is not - new positions only below that level.
The probability-weighted value across our three scenarios is $56.50, 29% above the current price of $43.87 - the market has not yet priced our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.
below $40.67 - below this level the upside to the base-case target ($58.00) is at least 2x the downside to the bear case ($32.00), the minimum risk/reward we require before committing new capital.
between $40.67 and $58.00 - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.
above $58.00 - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 25%.
if A material cut to full-year 2026 revenue or Adjusted EBITDA guidance, a renewed widening of GAAP net losses beyond consensus, or the loss of the USC partnership without replacement contracts would invalidate the thesis, regardless of price - the bear target of $32.00 is the backstop, not an arbitrary percentage stop.
Conviction Trend
Latest conviction: 59/100. Trend versus prior report: Down.
| Report date | Conviction |
|---|---|
| 2026-08-01 | 29 |
| 2026-07-25 | 59 |
| 2026-06-28 | 59 |
| 2026-05-30 | 54 |
| 2026-04-27 | 68 |
Sources
Market data: DYOR HQ proprietary market data workflow.
Public sentiment and news flow: public news flow including press releases distributed via BusinessWire, the company's official news page on tempus.com, third-party financial news and earnings-calendar aggregators, and analyst commentary distributed through TipRanks and CNN Markets.
Primary source types: SEC filings (8-K current reports filed with the SEC), company press releases and corporate news updates, earnings call and results announcements, and investor relations materials published by Tempus AI Inc.
Key sources
- Investor Relations | Tempus AI
- Tempus AI (TEM) Earnings Date and Reports 2026 $TEM
- Tempus AI, Inc. (TEM) Stock Price, News, Quote & History - Yahoo Finance
- Tempus AI, Inc. (TEM) Stock Price, Quote, News & Analysis | Seeking Alpha
- Tempus Reports First Quarter 2026 Results
- Tempus Reports First Quarter 2026 Results - Tempus
- Why Tempus AI (TEM) Is Up 5.5% After Major USC Precision-Medicine Data Partnership News
- Can Tempus AI's (TEM) USC Partnership Quietly Redefine Its Clinical Data Moat? - Simply Wall St News
- News Releases | Tempus AI
- List of 5 Acquisitions by Tempus (Apr 2026) - Tracxn
Data correct as of 2026-08-01.